In vitro, temozolomide was found to have a neglectable additive effect when in conjunction with BUB1 inhibition in glioblastoma54, suggesting that, while BUB1 might not be therapeutically useful in these tumours, its expression could aid in risk stratification for predicting efficacy to alkylating compounds. Here, BUB1 is linked to neoplasm.